1. Home
  2. For Consumers
  3. Women's Health
  4. OWH Education and Training
  5. Women's Health Events
  6. Previous OWH Events
  1. Women's Health Events

Previous OWH Events

From the FDA Office of Women's Health

Image
Woman watching program on laptop

On this page: Recent OWH events 

Recent OWH events

The FDA Office of Women’s Health (OWH) teams with various FDA collaborators and external partners to offer scientific and educational events on a variety of women’s health topics. When possible, we publicly post recordings of previous events. 

Please also see our Continuing Education (CE) page for a list of event recordings offering CE for health professionals. Don’t miss upcoming OWH events!

OWH hosted a webinar featuring guest speaker, Titilope Fasipe, MD, PhD, Co-Director, Sickle Cell & Thalassemia Program, Texas Children’s Hospital. The webinar discussed the clinical characteristics of sickle cell disease (SCD), advances in medical therapies to treat SCD, and the unique factors impacting women living with SCD. Dr. Fasipe explained the role of historical and systemic disparities on SCD health outcomes with emphasis on the impact on women, and discussed the consequences of national and state health policy initiatives on SCD. 

In observance of National Women's Health Week (NWHW) 2024 and National Osteoporosis Awareness and Prevention month, the FDA Office of Women’s Health (OWH), hosted a free virtual public webinar titled: Osteoporosis: A perspective for 2024 presented by Marcella Donovan Walker, MD, MS. Professor of Medicine at Columbia University Medical Center. The lecture summarized the current approach to assessing bone health, as well as preventing and treating osteoporosis with a focus on postmenopausal women.  

OWH hosted a Scientific Speaker Series lecture presented by Dineo Khabele, M.D., FACOG, FACS Mitchell & Elaine Yanow Professor and Chair of the Department of Obstetrics & Gynecology, Washington University School of Medicine. Dr. Khabele provided an overview of high-grade serious ovarian cancer (HGSOC) and discussed the challenges of early diagnosis and current treatment options. 

OWH, in collaboration with the Center for Drug Evaluation and Research (CDER) Office of Clinical Pharmacology (OCP), hosted a free public workshop including presentations and session discussions by experts in the fields of clinical pharmacology, obstetrics and gynecology, endocrinology, and clinical care. Speakers discussed the current understanding of the impact of menopause on the pharmacokinetics and pharmacodynamics (the movement of drugs through the body, and the body’s biological response to drugs, respectively), and exposure-response relationships of FDA-regulated drugs and biologics used by menopausal women for non-menopause-related indications.

 

Back to Top